NCT07018427View on ClinicalTrials.gov

Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

May 1, 2025

Study Completion Date

September 1, 2025

Conditions
Breast NeoplasmsTriple Negative Breast CancerHR+, HER2-, Advanced Breast CancerBreast Cancer
Interventions
DRUG

Sacituzumab Govitecan Monotherapy or Combination Therapy

The interventions in this study comprised either Sacituzumab Govitecan monotherapy or combination therapy. The specific combination regimens were determined based on real - world clinical practice patterns.

Trial Locations (1)

100010

Peking University Cancer Hospital & Institute, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER